Cost-effectiveness of screening compared to case-finding approaches to tuberculosis in long term care facilities for the elderly

International Journal of Epidemiology

Volumn 28, Issue 3, 1999, Pages 563-570

  Marchand, Robert ^a,b   Tousignant, Pierre ^a   Chang, Harvey ^c  

^a Regie Regionale S Serv Social M   (Canada)

^b Montreal Public Health Department   (Canada)

^c NONE

Author keywords

Aged; Cost effectiveness analysis; Markov chain; Nursing homes; Tuberculin test; Tuberculosis

Indexed keywords

AGED; ARTICLE; CHEMOPROPHYLAXIS; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; HEALTH CARE COST; HOSPITAL INFECTION; HUMAN; LONG TERM CARE; NURSING HOME; PRIORITY JOURNAL; TUBERCULIN TEST; TUBERCULOSIS;

AGED; ANTITUBERCULAR AGENTS; CANADA; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; HOMES FOR THE AGED; HUMANS; LONG-TERM CARE; MARKOV CHAINS; MASS SCREENING; QUALITY-ADJUSTED LIFE YEARS; TUBERCULIN TEST; TUBERCULOSIS;

EID: 0033063253     PISSN: 03005771     EISSN: None     Source Type: Journal    
DOI: 10.1093/ije/28.3.563     Document Type: Article

References (64)

1. Centers for Disease Control. Prevention and control of tuberculosis in institutions providing long-term care to the elderly. MMWR 1990; 39:RR10:11-20.
2. Reider HL, Kelly GD, Bloch AB, Cauthen GM, Snider DE. Tuberculosis diagnosed at time of death in the United States. Chest 1991;100: 678-81.
3. Abronheim JC, Bernhole HC, Clark WD. Age trends in autopsy rates: striking decline in late life. JAMA 1987;258:364-69.
4. Hutton M, Cauthen GM, Bloch AB. Result of a 29-state survey of tuberculosis in nursing homes and correctional institutions. Public Health Rep 1993;108:305-14.
5. Hoeppner VH, Ring ED. Tuberculosis in chronic care homes. Can Fam Physician 1987:33:1231-34.
6. MacArthur C, Enarson DA, Fanning EA, Hessel PA, Newman S. Tuberculosis among institutionalized elderly in Alberta, Canada. Int J Epidemiol 1992;21:1175-79.
7. Comité sur l'immunisation au Québec, Ministère de la Santé et des Services sociaux. La Tuberculose au Québec: État de la Situation. Gouvernement du Québec, 1994.
8. Marchand RS, Tousignant P. Tuberculose chez les persones âgées résidant en établissements au Québec: Le dépistage et la chimioprophylaxie sont-ils indiqués? Can J Public Health 1995;86:238-42.
9. Stead WW, Lofgren JP, Warren E, Thomas C. Tuberculosis as an endemic and nosocomial infection among the elderly in nursing homes. N Engl J Med 1985;312:1483-87.
10. Stead WW, To T. The significance of the tuberculin skin test in elderly persons. Ann Intern Med 1987;107:843-45.
11. Stead WW, To T, Harrison RW, Abraham JH. Benefit-risk considerations in preventive treatment for tuberculosis in elderly persons. Ann Intern Med 1987;107:837-42.
12. Rose DN, Silver AL, Schechter CB. The age threshold for izoniazid chemoprophylaxis: a decision analysis for low-risk tuberculin reactors. JAMA 1986;256:2709-13.
13. Tsevat J, Taylor WC, Wong JB, Pauker SG. Isoniazid for tuberculin reactors: take it or leave it. Am Rev Respir Dis 1988;137:215-20.
14. Rose D, Silver Al, Schechter CB. Preventive treatment for tuberculosis in the elderly. Ann Intern Med 1988;106:908.
15. Comstock GW. Prevention of tuberculosis among tuberculin reactors: maximizing benefits, minimizing risks. JAMA 1986;256:2729.
16. Snider DE. Decision analysis for isoniazide preventive therapy: take it or leave it? Am Rev Respir Dis 1988;137:2-3.
17. Cooper JK. Decision analysis for tuberculosis preventive treatment in nursing homes. J Am Geriatric Soc 1986;34:814-17.
18. Rose D, Silver AL, Schechter CB. Tuberculosis chemoprophylaxis for diabetics: are the benefits of isoniazid worth the risks? Mt Sinai J Med 1985;52:253-58.
19. Rose DN, Schechter CB, Fahs MC, Silver AL. Tuberculosis prevention: cost-effectiveness analysis of isoniazed chemoprophylaxis. Am J Prev Med 1988;4:102-09.
20. Fitgerald JM, Gafni A. A cost-effectiveness analysis of the routine use of isoniazid prophylaxis in patients with a positive Mantoux skin test. Am Rev Respir Dis 1990;142:848-53.
21. Beck RB, Pauker SG. The Markov medical process in medical prognosis. Med Decis Making 1983;3:419-57.
22. Dorken E, Grzybowski S, Allen EA. Significance of the tuberculin test in the elderly. Chest 1987;92:237-40.
23. Nairain JP, Lofgren JP, Warren E, Stead WW. Epidemic tuberculosis in a nursing home: a retrospective cohort study. J Am Geriatric Soc 1985;33:258-63.
24. Creditor MC, Smith EC, Gallai JB, Bauman M, Nelson KE. Tuberculosis, tuberculin reactivity and delayed cutaneous hypersensitivity in nursing home residents. J Gerontol 1988;43:97-100.
25. Comité provincial des maladies infectieuses sur l'évaluation du programme cadre de tuberculose produit en 1984. Tuberculose, une Approche Uniformisée d'Intervention de Type Santé Communautaire. Ministère de la Santé et des Services sociaux, Gouvernement du Québec, 1990.
26. Perez-Stable EJ, Flaherty D, Schecter G, Slutkin G, Hopewell PC. Conversion and revision of tuberculin reactions in nursing home residents. Am Rev Respir Dis 1988;137:801-04.
27. Gordin FM, Perez-Stable EJ, Flaherty D et al. Evaluation of a third sequential tuberculin test in a chronic care population. Am Rev Respir Dis 1988;137:153-57.
28. Comstock GW, Edwards PQ. The competing risks of tuberculosis and hepatitis for adult tuberculin reactors. Am Rev Respir Dis 1975;111: 573-77.
29. Ferebee GW, Mount FW, Murray FJ et al. A controlled trial of izoniazid prophylaxis in mental institution. Am Rev Respir Dis 1963;88:161-75.
30. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT TRIAL. Bull World Health Organ 1982;60:555-64.
31. Grzybowski S, Ashley MJ, Pliskin G. Chemoprophylaxis in inactive tuberculosis: long-term evaluation of a Canadian trial. Can Med Assoc J 1976;114:607-11.
32. Oscarsson PN, Silver H II. Incidence of pulmonary tuberculosis among diabetics. Acta Med Scand 1958;161(Suppl.335):23-48.
33. Thorn PA, Brookes VS, Waterhouse JAH. Peptic ulcers, partial gastrectomy and pulmonary tuberculosis. Br Med J 1956;i:603-60.
34. Tverdal A. Body mass index and incidence of tuberculosis. Eur J Respir Dis 1986;69:355-62.
35. Reider HL, Cauthen GM, Comstock GW, Snider DE. Epidemiology of tuberculosis in the United States. Epidemiol Rev 1989;11:79-98.
36. Feld R, Body GP, Groschel D. Mycobacteriosis in patients with malignant disease. Arch Intern Med 1976;136:67-70.
37. Veening GJJ. Long term isoniazid prophylaxis. Controlled trial on INH prophylaxis after recent tuberculin conversion in young adults. Bull UN Int Tuberc 1968;41:169-71.
38. Centers for Disease Control. Tuberculosis in blacks - United States. MMWR 1987;36:212-20.
39. Direction générale de la santé publique. Tuberculose, Rapport Annuel de 1992. Québec: Ministère de la Santé et des Services sociaux, 1993.
40. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis: a general review. Adv Tuberc Res 1970;17:28-106.
41. Kopanoff DE, Snider DE, Caras GJ. Isoniazid-related hepatitis: a US Public Health Service cooperation surveillance study. Am Rev Respir Dis 1978;117:991-1001.
42. Dash LA, Comstock GW, Flynn JPG. Izoniazid preventive therapy. Am Rev Respir Dis 1980;121:1039-44.
43. Byrd RB, Horn BR, Solomon DA, Griggs GA. Toxic effects of isoniazid in tuberculosis chemoprophylaxis. JAMA 1979;241:1239-41.
44. Welty C, Burstin S. Muspratt S, Tager IB. Epidemiology of tuberculosis infection in a chronic care population. Am Rev Respir Dis 1985;132: 133-36.
45. Bustin SJ, Muspratt JA, Rossing TH. Studies of the dynamics of reactivity to tuberculin and candida antigen in institutionalized patients. Am Rev Resp Dis 1986;134:1072-74.
46. Direction générale de la santé publique. Tuberculose, Rapport Annuel de 1988. Québec: Ministère de la Santé et des Services sociaux, 1989.
47. Direction générale de la santé publique. Tuberculose, Rapport Annuel de 1989. Québec: Ministère de la Santé et des Services sociaux, 1990.
48. Direction générale de la santé publique. Tuberculose, Rapport Annuel de 1990. Québec: Ministère de la Santé et des Services sociaux, 1991.
49. Direction générale de la santé publique. Tuberculose, Rapport Annuel de 1991. Québec: Ministère de la Santé et des Services sociaux, 1992.
50. Ministère de la Santé et des Services sociaux. Rapport Statistique Annuel, Hébergement 1991-1992 (AS 479), Gouvernement du Québec.
51. Duchesne L. La Situation Démographique au Québec. Ed. Les publications du Québec, Québec, 1990.
52. Sackett DL, Torrance GW. The utility of different states as perceived by the general public. J Chronic Dis 1978;31:697-704.
53. Marchand R. Évaluation économique du dépistage et de la chimioprophylaxie de la tuberculose dans les établissements pour personnes âgées [MSc. thesis]. Montreal (Qc): McGill University, 1993.
54. Régie de l'assurance maladie du Québec. Manuel des omnipraticiens: régime d'assurance-maladie et d'assurance-hospitalisation. Québec: Service des Communications, 1992.
55. Pressat R. L'Analyse Démographique, Concepts Méthodes et Résultats. Paris: Presses Universitaires de France, 1973.
56. Eisenberg JM. Clinical economics: a guide to the economic analysis of clinical practices. JAMA 1989;262:2879-86.
57. Ganiats TG. Prevention, policy, and paradox: what is the value of future health? Am J Prev Med 1997;13:12-17.
58. Colice G. Decision analysis, public health policy, and isoniazid chemoprophylaxix for young adult tuberculin skin reactors. Arch Intern Med 1990;159:2517-22.
59. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Temptative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992;146:473-81.
60. Teng TO, Adams ME, Pliskin JS et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 1995;15:369-90.
61. Riddiough MA, Sisk JE, Bell JC. Influenza vaccination: cost-effectiveness and public policy. JAMA 1983;249:3189-95.
62. Sisk JE, Riegleman RK. Cost effectiveness of vaccination against pneumococcal pneumonia: an update. Ann Intern Med 1986;104:79-86.
63. Edelson JT, Weinstein MC, Tosteson AN, Williams L, Lee TH, Goldman L. Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension. JAMA 1990;263:408-13.
64. Alberta Health, Tuberculosis Services. Tuberculosis Control and Management Project for Continuing Care. Edmonton: Alberta Health, 1996.